

### **Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

### **Listing of Claims**

1-27. (Canceled)

28. (Currently amended) A stable oral composition comprising a therapeutically effective amount of desloratadine, meglumine, and pharmaceutically acceptable excipient;  
wherein the desloratadine is stable to the extent that after 3 months at 40 °C and 75% relative humidity less than 0.5 %w/w of the N-formyl impurity of desloratadine has formed.

29. (Previously presented) The stable oral composition of claim 28, further comprising antioxidant.

30. (Previously presented) The stable oral composition of claim 29, wherein the antioxidant comprises butylated hydroxytoluene.

31. (Previously presented) The stable oral composition of claim 29, wherein the antioxidant is in an amount of about 0.01% to about 5% by weight of the composition.

32. (Previously presented) The stable oral composition of claim 28, wherein meglumine is in an amount of about 0.01% to about 5% by weight of the composition.

33. (Canceled)

34. (Previously presented) The stable oral composition of claim 28, wherein the composition does not undergo discoloration, when stored at 40°C and 75% relative humidity over a period of 3 months.

35. (New) A stable oral composition comprising:

a therapeutically effective amount of desloratadine,  
about 0.01% to about 5% by weight meglumine, and  
a pharmaceutically acceptable excipient;

wherein the meglumine is effective stabilize the desloratadine to the extent that after 3 months at 40 °C and 75% relative humidity less than 0.5 %w/w of the N-formyl impurity of desloratadine has formed.